Adenosine A2a Receptor antibody (AA 273-301) (Biotin)

Catalog No. ABIN1891632

This anti-Adenosine A2a Receptor antibody is a Rabbit Polyclonal antibody detecting Adenosine A2a Receptor in WB, ELISA, IF and ICC. Suitable for Human.

Quick Overview for Adenosine A2a Receptor antibody (AA 273-301) (Biotin) (ABIN1891632)

Target: Adenosine A2a Receptor (ADORA2A)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Adenosine A2a Receptor antibody is conjugated to Biotin

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Product Details anti-Adenosine A2a Receptor Antibody (Biotin)

Binding Specificity: AA 273-301

Specificity: This ADORA2A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 273-301 amino acids from the Central region of human ADORA2A.

Purification: Affinity purified

Isotype: IgG

Application Details

Application Notes: Approved: ELISA, ICC, IF, WB

Usage: The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.

Comment:

Target Species of Antibody: Human

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: PBS, no preservatives added

Preservative: Without preservative

Handling Advice: Aliquot to avoid repeated freezing and thawing.

Storage: 4 °C,-20 °C

Storage Comment: Short term: store at 4°C. Long term: aliquot and store -20°C for up to 6 months. Avoid freeze-thaw cycles. Protect from light.

Expiry Date: 6 months

Target Details for Adenosine A2a Receptor

Target: Adenosine A2a Receptor (ADORA2A)

Alternative Name: ADORA2A/Adenosine A2A Receptor

Background: Name/Gene ID: ADORA2A
Subfamily: Adenosine
Family: GPCR

Synonyms: ADORA2A, Adenosine receptor A2a, ADORA2, A2a receptor, Adenosine A2a receptor, Adenosine A2 receptor, Adenosine receptor subtype A2a, HA2aR, RDC8

Gene ID: 135

Pathways: Neurotrophin Signaling Pathway, cAMP Metabolic Process, Synaptic Membrane, Feeding Behaviour, Cancer Immune Checkpoints